IL6 and chronic graft versus host disease: These agents suppress key pro-inflammatory cytokines, including interferon-gamma (IFN-γ) and interleukin-6 (IL-6), downregulate antigen-presenting cell (APC) activity, and expand regulatory T cells (Tregs), thereby promoting a tolerogenic immune environment in both acute and chronic GVHD [9,31].